About This Fund
Kurma Growth Opportunities Fund is a growth equity vehicle managed by Kurma Partners, a Paris-based specialist investor dedicated to European biotechnology and life sciences. Announced in March 2022 with a first closing of €160 million against a €250 million target, the fund represents Kurma Partners's inaugural growth-stage investment vehicle, a purpose-built complement to the firm's established early-stage Biofund series (Biofunds I–IV). The Kurma Growth Opportunities Fund focuses on unlisted European companies in biotech and healthtech at a pivotal transition point: moving from research and development validation to commercial-stage operations. The fund targets approximately 15 portfolio companies addressing significant unmet medical needs, providing growth capital to businesses ready to accelerate their paths to market — including late-stage clinical-stage biotech companies and digital health platforms approaching commercialization. The fund's investment mandate is backed by the Tibi label, making it eligible for the €6 billion French institutional initiative for innovative European company growth. A distinguished group of institutional limited partners participated in the first closing, including the European Investment Fund (EIF), Bpifrance, the Belgian Growth Fund (managed by PMV), BNP Paribas Fortis Private Equity, the SFPI, BNP Paribas Fortis, Groupe Pasteur Mutualité, and Eurazeo as anchor investor. With Kurma Partners crossing €1 billion in total assets under management following the €215 million final close of Biofund IV in April 2026, the Growth Opportunities Fund cements the firm's position as a comprehensive lifecycle investor in European life sciences — covering seed-stage discovery through commercial-stage scale-up.